Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET
Mechanisms Underlying Species Differences in Hepatotoxicity
Quantitative Systems Toxicology (QST) modeling can explain and predict species differences in dose-dependent hepatotoxicity.
DILIsym Services, an SLP Company, Launches Consortium for Drug-Related Kidney Injury
RENAsym consortium will use QST to predict and investigate drug-induced kidney injury across various patient groups
Enzyme and Transporter Expression Levels in GastroPlus® 9.6
This video discusses the enzyme and transporter expression levels that are defined in various tissues, e.g., GI tract, liver, lung, kidney and species (human, dog, monkey, and rat).
In vitro and in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET Predictor™
Riociguat, a guanyl cyclase inhibitor, is one of its kind drug regimen approved for management of pulmonary arterial hypertension and chronic thromboembolism pulmonary hypertension.
Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Software (DILIsym)
Lixivaptan, a vasopressin-2 receptor antagonist, is being developed for the treatment of autosomal-dominant polycystic kidney disease (ADPKD), an orphan disease that is an unmet medical need.
Assessing the Role of Intracellular Binding Protein in Drug-Induced Bile Acid Transporter Inhibition Using Quantitative Systems Pharmacology (QSP) Modeling
Bile acid transporter inhibition has been shown to be an important mechanism of drug-induced liver injury (DILI), but the biophase responsible for the transporter inhibition is unclear.
Assessing the Role of Intracellular Binding Protein in Drug-Induced Bile Acid Transporter Inhibition Using QuantiativeSystems Pharmacology (QSP) Modeling
DILIsym Is Used to Predict Bile-Acid Mediated Drug-Induced Liver Injury
A PBPK model of the negative effect of chitosan on acyclovir absorption: The mucus-chitosan interaction
A recent bioavailability study raises questions about the universality of the permeability enhancing effect of chitosan on poorly permeable drugs.
HTPK: Conducting PK modeling and simulations at high speed
In silico pharmacokinetic (PK) simulations are now routinely incorporated into drug development workflows, especially in the later stages.
HTPK: Conducting PK modeling and simulations at high speed
HTPK lightens the burden of collecting and preparing input variables for full blown PK simulations by using structure-based predictions.
Using in-silico Models to Integrate in-vitro Data to Support Virtual Trials for Cost Effective Drug Development
PBPK models allow incorporating different types of in vitro measurements into single platform to account for all processes affecting drug’s absorption, distribution and elimination.
Integration of Precipitation Kinetics From an In vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs
Solubility, dissolution, and precipitation in the gastrointestinal tract can be critical for the oral bioavailability of weakly basic drugs.
Application of a Dynamic Fluid & pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus™
The application of preclinical in vitro and in silico models can help formulation scientists to predict the in vivo performance of a drug in an early stage of oral drug product development.
In Silico Simulation of Dissolution Profiles for Development of Extended-Release Doxazosin Tablets
Developing extended-release (ER) formulations with appropriate release characteristics can be challenging for formulation scientists.
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
Bile salt export pump (BSEP) inhibition has emerged as an important mechanism that may contribute to the initiation of human drug-induced liver injury (DILI).
Molecular Drivers of Crystallization Kinetics for Drugs in Supersaturated Aqueous Solutions
In this study, we explore molecular properties of importance in solution-mediated crystallization occurring in supersaturated aqueous drug solutions.
Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity
CKA, a chemokine receptor antagonist intended for treating inflammatory conditions, produced dose-dependent hepatotoxicity in rats but advanced into the clinic where single doses of CKA up to 600 mg appeared safe in humans.
Drug discovery and computational strategies in the multitarget drugs era
The pharmaceutical industry is increasingly joining chemoinformatics in the search for the development of new drugs to be used in the treatment of diseases.
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)
H3B-6545, a novel selective estrogen receptor (ER)α covalent antagonist (SERCA) which inactivates both wild-type and mutant ERα, is in clinical development for the treatment of metastatic breast cancer.